Idiopathic intracranial hypertension (also known as pseudotumor cerebri) is a syndrome of elevated intracranial pressure without an identifiable structural cause, most commonly affecting obese women of childbearing age (>95% of cases). [1-2] Incidence is 1–2 per 100,000 in the general population but rises to 19–21 per 100,000 in overweight/obese women aged 20–44. [2-3] The two overarching treatment goals are preservation of vision and alleviation of headache. [4]
1. History
- Headache: Most common presenting symptom (84%); often constant or daily, may worsen in the morning or with Valsalva-like maneuvers (coughing, straining, bending) [1][5]
- Transient visual obscurations (TVOs): Brief episodes of graying or blacking out of vision, often positional (68%) [1]
- Pulsatile tinnitus: Pulse-synchronous whooshing sound (52%); ask about unilateral vs. bilateral [1]
- Visual loss: Persistent blurred vision or visual field constriction (32%) [1]
- Diplopia: Horizontal, from CN VI palsy (18%) [1]
- Neck/back pain: Present in 53% [1]
- Timing: Ask about recent weight gain, which often precedes symptom onset [1]
- Important negatives: Fever, focal neurologic deficits (other than CN VI), altered mental status, seizures, positional headache improvement (suggests intracranial hypotension instead)
2. Alarm Features
- Rapidly progressive visual loss (fulminant IIH: severe vision loss within 4 weeks of symptom onset) — requires emergent surgical intervention [1][6]
- Severe papilledema with reduced visual acuity
- New CN VI palsy with worsening diplopia
- Atypical demographics (male, non-obese, elderly, pediatric) — heighten suspicion for secondary causes such as cerebral venous sinus thrombosis, mass lesion, or meningitis [1][7]
- Focal neurologic deficits beyond CN VI palsy
- Altered consciousness, nausea/vomiting suggesting acutely elevated ICP
- CSF rhinorrhea or otorrhea (skull base CSF leak) [1]
3. Medications
Causative/contributing medications to exclude (secondary intracranial hypertension): [1][8-9]
- Strongly associated: Tetracycline-class antibiotics (minocycline, doxycycline), vitamin A derivatives/retinoids (isotretinoin), recombinant growth hormone, lithium
- Moderately associated: Corticosteroid withdrawal
- Weakly associated: Cyclosporine, progestin-only contraceptives, fluoroquinolones, danazol, divalproic acid
Treatment medications
- Acetazolamide (first-line): 500 mg extended-release BID–QID (1–4 g/day); titrate up over days to reduce side effects (paresthesias, nausea, dysgeusia, metabolic acidosis). Safe in pregnancy [1][4]
- Topiramate: Alternative carbonic anhydrase inhibitor; may also promote weight loss [1]
- GLP-1 receptor agonists (semaglutide, etc.): Emerging role for weight loss and possible direct ICP reduction via CSF secretion inhibition [1-2]
Contraindicated: Corticosteroids — no evidence of benefit and cause weight gain. [4] Oral contraceptives do NOT need to be discontinued [1]
4. Diet
- Low-sodium, calorie-restricted diet is recommended alongside acetazolamide (supported by the IIH Treatment Trial) [4]
- Weight loss target: ~1 lb/week until 5–10% total body weight loss; 6% weight loss linked to papilledema resolution, though 15–24% may be needed for full disease remission [2]
- Fluid restriction may be helpful adjunctively [4]
- Long-term: Bariatric surgery for BMI ≥35 with failed lifestyle interventions (grade A recommendation); multicomponent lifestyle intervention (diet + exercise + behavioral) for BMI <35 (grade B) [10]
5. Review of Systems
- Neuro: Headache character/timing, TVOs, diplopia, cognitive complaints, neck stiffness
- Ophthalmologic: Blurred vision, visual field loss, photopsia
- ENT: Pulsatile tinnitus, hearing changes, nasal drainage (CSF leak), ear fullness
- Endocrine: Menstrual irregularity, recent weight gain, symptoms of thyroid disease, Cushing syndrome
- Psychiatric: Depression, anxiety (quality of life is significantly impacted) [11]
6. Collateral History and Family History
- Medication reconciliation: Specifically ask about tetracyclines, retinoids, vitamin A supplements, growth hormone, lithium [8]
- Recent weight changes: Quantify amount and timeline
- Sleep history: Obstructive sleep apnea is a secondary cause of intracranial hypertension [12]
- Family history: No strong hereditary pattern, but family history of obesity, metabolic syndrome, and migraine is relevant
- Social context: Impact on driving, work, daily function; access to dietary/weight management resources
7. Risk Factors
- Obesity (present in ~90% of cases; strongest modifiable risk factor) [2]
- Female sex, reproductive age (20–40 years) [1]
- Recent weight gain (even 5–15% increase) [1]
- Black ethnicity (associated with increased risk of visual loss) [11]
- Anemia, renal disease, systemic hypertension [7][11]
- Obstructive sleep apnea [12]
- Medication exposure (tetracyclines, retinoids, etc.) [8]
8. Differential Diagnosis
Dangerous cannot-miss diagnoses: [11]
- Cerebral venous sinus thrombosis — can mimic IIH exactly; excluded by MR venography
- Intracranial mass lesion (tumor, abscess) — excluded by MRI
- Meningitis (infectious, carcinomatous, inflammatory) — excluded by CSF analysis
- Dural arteriovenous fistula [1]
Other important differentials
- Drug-induced intracranial hypertension (tetracyclines, retinoids) — phenotypically identical to IIH [8][13]
- Chronic migraine — significant symptom overlap; ~80% of IIH patients have comorbid migraine [14]
- Spontaneous intracranial hypotension — positional headache (worse upright, better supine) is the distinguishing feature [14]
- Optic neuritis — unilateral disc edema with pain on eye movement, RAPD
- Bilateral papilledema from systemic hypertension (malignant hypertension)
9. Past Medical History
- Prior episodes of IIH (recurrence rate ~16.5%) [13]
- Obesity trajectory and prior weight loss attempts
- History of bariatric surgery
- Prior lumbar punctures or CSF diversion procedures
- Migraine history
- Endocrine disorders (PCOS, thyroid disease, Cushing syndrome)
- Anemia, renal disease, systemic hypertension [7]
- Venous thromboembolism history (raises concern for cerebral venous thrombosis)
10. Physical Exam
- Fundoscopy: Papilledema is the most important sign and usually the only one; grade using the Frisén scale. Absent in ~5% of cases [1][15]
- Visual acuity: Snellen chart; may be preserved until late
- Visual fields: Confrontation fields at bedside; formal perimetry (Humphrey) is essential for monitoring
- Pupillary exam: Check for relative afferent pupillary defect (RAPD) — suggests optic nerve damage
- Extraocular movements: CN VI palsy (lateral rectus weakness → esotropia, horizontal diplopia)
- Vital signs: Blood pressure (exclude malignant hypertension), BMI calculation
- Neurologic exam: Should be otherwise normal; focal deficits beyond CN VI suggest alternative diagnosis [4]
11. Lab Studies
- CSF analysis (from diagnostic LP): Opening pressure, glucose, protein, cell count, cytology — must be normal in composition for IIH diagnosis [1][4]
- Opening pressure ≥25 cm H₂O (250 mm H₂O) is diagnostic threshold in adults [1][4]
- Basic metabolic panel: Baseline before starting acetazolamide (though routine monitoring may be omitted in otherwise healthy patients) [1]
- CBC: Rule out anemia (risk factor for visual loss) [11]
- Thyroid function tests, cortisol if endocrinopathy suspected [7]
- Pregnancy test in women of childbearing age
- Vitamin A level if retinoid exposure suspected
12. Imaging
First-line: Brain MRI with and without gadolinium + MR venography [1][14]
- Rules out mass lesion, hydrocephalus, meningeal enhancement, cerebral venous sinus thrombosis
- Positive MRI signs of IIH: transverse sinus stenosis (94% of patients), partially empty sella, posterior globe flattening, optic nerve sheath distension, optic nerve tortuosity, cerebellar tonsillar descent [1][16]
The following figure demonstrates characteristic MRI findings in IIH, including partially empty sella and bilateral transverse sinus stenosis:
CT head: Adequate to exclude mass lesion emergently but inferior to MRI for IIH evaluation [1]
Point-of-care ultrasound: Optic nerve sheath diameter (ONSD) >5 mm suggests elevated ICP, though threshold values range from 4.8–6.3 mm across studies [5]
When imaging is unnecessary: Repeat imaging is not routinely needed if diagnosis is established and clinical course is stable
13. Special Tests
- Lumbar puncture with opening pressure: Gold standard for confirming elevated ICP; measure in lateral decubitus position; ≥25 cm H₂O is diagnostic. Remove 30–40 mL CSF therapeutically when pressure is high [1][4]
- Optical coherence tomography (OCT): Quantifies retinal nerve fiber layer thickness; useful for monitoring papilledema and optic atrophy over time [15]
- Automated visual field testing (Humphrey perimetry): Essential for baseline and serial monitoring; enlarged blind spot and concentric constriction are typical patterns [14]
- Optic nerve sheath ultrasound: ONSD measurement as a bedside screening tool [5]
- Digital subtraction angiography with venous manometry: Reserved for patients being considered for venous sinus stenting; measures trans-stenotic pressure gradient (>10 mm Hg typically required for stenting) [17]
14. ECG
ECG is not a primary diagnostic tool for IIH. However, there are relevant considerations:
- Elevated ICP from any cause can produce repolarization changes (T-wave inversions, QT prolongation, ST changes, "cerebral T waves"), though these are more commonly associated with acute neurologic emergencies (SAH, stroke) than chronic IIH [18]
- IIH patients have an independently increased cardiovascular risk (>2× risk of cardiovascular events vs. BMI-matched controls), warranting attention to cardiovascular screening [19-20]
- ECG may be indicated as part of general workup given the high prevalence of obesity, hypertension, and metabolic comorbidities in this population
15. Assessment
Typical presentation: Obese woman aged 20–40 with progressive headache, TVOs, pulsatile tinnitus, and papilledema on fundoscopy, with normal neuroimaging and elevated CSF opening pressure. [1][14]
Severity stratification
- Mild: Headache with low-grade papilledema, preserved visual acuity and fields
- Moderate: Moderate papilledema with visual field defects but preserved acuity
- Severe/Fulminant: Rapid visual loss within days to weeks, high-grade papilledema, reduced visual acuity — constitutes a neuro-ophthalmologic emergency [1][6]
Complications: Permanent visual field loss, optic atrophy, blindness (if untreated), chronic disabling headache, CSF leak (rhinorrhea, otorrhea), reduced quality of life [1][11]
16. Treatment Plan
The following figure summarizes the multimodal management approach:
Initial stabilization (ED/acute)
- Diagnostic/therapeutic LP: Remove 30–40 mL CSF to acutely lower ICP; often provides transient symptomatic relief. Lasting remission after a single LP is not uncommon [1][4]
- Start acetazolamide: 500 mg ER BID, titrate up to 1–4 g/day as tolerated [1][4]
- Discontinue offending medications (tetracyclines, retinoids) [4]
Outpatient management
- Weight loss: Cornerstone of treatment; target 5–10% body weight loss. Consider GLP-1 agonists for weight management. Bariatric surgery for BMI ≥35 with refractory disease [1-2][4][10]
- Acetazolamide: Continue and titrate based on symptoms and visual function [1]
- Migraine-specific therapy may be needed for persistent headache even after ICP normalization [14]
Surgical interventions (for fulminant IIH or progressive visual loss despite medical therapy): [1][4]
- Optic nerve sheath fenestration: Preferred when visual loss is primary concern with minimal headache
- CSF shunting (ventriculoperitoneal or lumboperitoneal): Preferred when both visual loss and headache are significant
- Venous sinus stenting: Emerging option for patients with significant transverse sinus stenosis and pressure gradient >10 mm Hg [17]
- Temporary lumbar drain: Bridge to definitive surgery in fulminant cases [1][6]
Steroids are contraindicated — no benefit and promote weight gain [4]
17. Disposition
Admission criteria
- Fulminant IIH: Severe or rapidly progressive visual loss — requires emergent neurosurgical/neuro-ophthalmologic consultation [1][6]
- Inability to perform urgent outpatient neuro-ophthalmology follow-up
- Need for temporary CSF drainage
- Severely elevated opening pressure with significant visual compromise
Observation indications
- New diagnosis with moderate papilledema and visual field defects, pending neuro-ophthalmology evaluation
- Post-LP monitoring
Discharge criteria
- Mild papilledema with preserved visual acuity and fields
- Able to start acetazolamide and arrange close outpatient follow-up (neuro-ophthalmology within 1–2 weeks)
- Reliable patient with understanding of return precautions
Specialist consultation triggers
- Neuro-ophthalmology: All confirmed or suspected cases [14]
- Neurosurgery/neurointerventional: Fulminant disease, refractory to medical therapy, or consideration for stenting/shunting [1]
- Bariatric surgery: BMI ≥35 with failed weight loss attempts [10]
18. Follow Up / Return Precautions
Follow-up timing
- Neuro-ophthalmology within 1–2 weeks of diagnosis for formal visual field testing and OCT baseline
- Repeat visual fields every 1–3 months during active treatment
- Long-term monitoring is essential — relapses years later are not uncommon [15]
Return precautions (counsel patients to return immediately for):
- New or worsening vision loss or blurred vision
- Increasing frequency of TVOs
- New double vision
- Severe worsening headache unresponsive to usual treatment
- New nasal or ear drainage (CSF leak)
Patient counseling
- Weight loss is the most important long-term intervention and can lead to disease remission [2][4]
- Acetazolamide side effects (tingling, carbonated drink taste change, fatigue) are common but usually tolerable
- Headache may persist even after ICP normalizes and may require separate migraine management [14]
- Expected recovery: With appropriate treatment, prognosis is generally good, but permanent visual field loss occurs in a significant minority [11]
References
1. Idiopathic Intracranial Hypertension. — Horton JC. The New England Journal of Medicine. 2025.
2. GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension. — Sioutas GS, Mualem W, Reavey-Cantwell J, Rivet DJ. JAMA Neurology. 2025.
3. Cerebrospinal Fluid Analysis. — Shahan B, Choi EY, Nieves G. American Family Physician. 2021.
4. Headache Arising From Idiopathic Changes in CSF Pressure. — Ducros A, Biousse V. The Lancet. Neurology. 2015.
5. A Review of the Clinical Presentation, Causes, and Diagnostic Evaluation of Increased Intracranial Pressure in the Emergency Department. — Olaru C, Langberg S, McCoin NS. The Western Journal of Emergency Medicine. 2024.
6. Fulminant Idiopathic Intracranial Hypertension. — Bouffard MA. Current Neurology and Neuroscience Reports. 2020.
7. Diagnosis of Idiopathic Intracranial Hypertension - The Importance of Excluding Secondary Causes: A Systematic Review. — Kilic K, Korsbæk JJ, Jensen RH, Cvetkovic VV. Cephalalgia : An International Journal of Headache. 2022.
8. Drug-Induced Intracranial Hypertension: A Systematic Review and Critical Assessment of Drug-Induced Causes. — Tan MG, Worley B, Kim WB, Ten Hove M, Beecker J. American Journal of Clinical Dermatology. 2020.
9. Idiopathic Intracranial Hypertension. — Ball AK, Clarke CE. The Lancet. Neurology. 2006.
10. Weight Management Interventions for Adults With Idiopathic Intracranial Hypertension: A Systematic Review and Practice Recommendations. — Abbott S, Chan F, Tahrani AA, et al. Neurology. 2023.
11. Diagnosis and Clinical Features of Common Optic Neuropathies. — Biousse V, Newman NJ. The Lancet. Neurology. 2016.
12. Phenotyping Non-Idiopathic Pseudotumor Cerebri Syndrome - A Prospective Cohort Study. — Svart K, Jensen RH, Høgedal L, et al. Cephalalgia : An International Journal of Headache. 2022.
13. A Comparison Between the Clinical Features of Pseudotumor Cerebri Secondary to Tetracyclines and Idiopathic Intracranial Hypertension. — Orme DR, Vegunta S, Miller MA, et al. American Journal of Ophthalmology. 2020.
14. Diagnosis and Management of Headache: A Review. — Robbins MS. The Journal of the American Medical Association. 2021.
15. An Update on Idiopathic Intracranial Hypertension in Adults: A Look at Pathophysiology, Diagnostic Approach and Management. — Toscano S, Lo Fermo S, Reggio E, et al. Journal of Neurology. 2021.
16. MRI Findings as Markers of Idiopathic Intracranial Hypertension. — Barkatullah AF, Leishangthem L, Moss HE. Current Opinion in Neurology. 2021.
17. Indications for the Performance of Intracranial Endovascular Neurointerventional Procedures: A Scientific Statement From the American Heart Association. — Eskey CJ, Meyers PM, Nguyen TN, et al. Circulation. 2018.
18. The Heart-Brain-Metabolism Axis in Cardiovascular and Neurologic Disease. — Tardo DT, Cortes-Canteli M, Fuster V, Sachdev PS, Kovacic JC. Journal of the American College of Cardiology. 2025.
19. Association Between Idiopathic Intracranial Hypertension and Risk of Cardiovascular Diseases in Women in the United Kingdom. — Adderley NJ, Subramanian A, Nirantharakumar K, et al. JAMA Neurology. 2019.
20. Prevalence of Cardiovascular and Cerebrovascular Disease in Idiopathic Intracranial Hypertension. — Trinh I, Shaia JK, Kaelber D, et al. Clinical Neurology and Neurosurgery. 2025.
21. Progress and recognition of idiopathic intracranial hypertension: A narrative review. — Zhou C, Zhou Y, Liu L, et al. CNS Neuroscience & Therapeutics. 2024.